Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Authors Ian Hamilton-Craig, Karam Kostner, David Colquhoun, et al

Published Date November 2010 Volume 2010:6 Pages 1023—1037

DOI http://dx.doi.org/10.2147/VHRM.S13496

Published 10 November 2010

Ian Hamilton-Craig1, Karam Kostner2, David Colquhoun2, Stan Woodhouse2
1Griffith University School of Medicine, Southport, Queensland, Australia; 2University of Queensland, Brisbane, Queensland, Australia

Abstract: High-dose potent statin therapy in combination with ezetimibe is now standard practice for the treatment of adult patients with heterozygous familial hypercholesterolemia (heFH), as the result of numerous studies in patients with primary hypercholesterolemia or heFH. These studies have shown the combination to be both effective and safe in the short to medium term. Recently, short-term ezetimibe therapy has also been shown to be effective and safe in combination with statin therapy for children and adolescents with heFH. Effective statin–ezetimibe combination therapy is capable of achieving near-normal lipid profiles in heFH patients, with expected improvement in risk for cardiovascular disease (CVD) and improved life expectancy resulting predominantly from reduction in levels of low-density lipoprotein cholesterol. There are few data to support a pleiotropic action of ezetimibe with regard to CVD benefit, unlike therapy with statins. No serious and unexpected clinical adverse effects of combination statin–ezetimibe therapy have emerged till date, although data are limited in children and adolescents, for whom longer-term studies are required. Recent data suggesting possible proatherogenic effects of ezetimibe require confirmation. One large long-term randomized controlled clinical outcomes trial is in progress in non-FH patients to determine the efficacy and safety of ezetimibe therapy; it is unlikely that such a trial will ever be performed in patients with FH.

Keywords: familial hypercholesterolemia, ezetimibe, statin, combination therapy, low-density lipoprotein cholesterol

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells [Corrigendum]

Yu L, Wang XL, Zhu D, Ding WC, Wang LM, Zhang CL, Jiang XH, Shen H, Liao SJ, Ma D, Hu Z, Wang H

OncoTargets and Therapy 2015, 8:365-366

Published Date: 4 February 2015

An anthropometric study to evaluate the correlation between the occlusal vertical dimension and length of the thumb

Basnet BB, Parajuli PK, Singh RK, Suwal P, Shrestha P, Baral D

Clinical, Cosmetic and Investigational Dentistry 2015, 7:33-39

Published Date: 3 February 2015

Increased risk of posterior circulation infarcts among ischemic stroke patients with cervical spondylosis

Chen CC, Chung CY, Lee TH, Chang WH, Tang SF, Pei YC

Neuropsychiatric Disease and Treatment 2015, 11:273-278

Published Date: 3 February 2015

Maternal and neonatal tetanus elimination: from protecting women and newborns to protecting all

Khan R, Vandelaer J, Yakubu A, Raza AA, Zulu F

International Journal of Women's Health 2015, 7:171-180

Published Date: 3 February 2015

Ag-plasma modification enhances bone apposition around titanium dental implants: an animal study in Labrador dogs

Qiao SC, Cao HL, Zhao X, Lo HW, Zhuang LF, Gu YX, Shi JY, Liu XY, Lai HC

International Journal of Nanomedicine 2015, 10:653-664

Published Date: 14 January 2015

Synthesis, pharmacokinetics, and biological use of lysine-modified single-walled carbon nanotubes [Erratum]

Mulvey JJ, Feinberg EN, Alidori S, McDevitt MR, Heller DA, Scheinberg DA

International Journal of Nanomedicine 2015, 10:595-596

Published Date: 14 January 2015

Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy

Campbell NL, Skaar TC, Perkins AJ, Gao S, Li L, Khan BA, Boustani MA

Clinical Interventions in Aging 2015, 10:269-275

Published Date: 14 January 2015

Optimal management of familial hypercholesterolemia: treatment and management strategies

Mohammad Hassan Nemati, Behrooz Astaneh

Vascular Health and Risk Management 2010, 6:1079-1088

Published Date: 3 December 2010

Blood flow interplays with elastin: collagen and MMP: TIMP ratios to maintain healthy vascular structure and function

Poulami Basu, Utpal Sen, Neetu Tyagi,  et al

Vascular Health and Risk Management 2010, 6:215-228

Published Date: 30 March 2010